2023-09 – Q2 2023 Reporting

  • Screening of patients in New Zealand has now improved after visiting the clinical centres involved in SER150 CL-009 study.
  • To facilitate enrolment, the entrance criteria will be revised for the SER150 CL-009 study based on feedback from investigators and serial blood collections will be removed from the protocol. 
  • The company has initiated a share issue through a private placement to raise funds to finalize the SER150 Cl-009 clinical study.

Read more here